PuroA-OH

General Information


DRACP ID  DRACP02831

Peptide Name   PuroA-OH

Sequence  FPVTWRWWKWWKG

Sequence Length  13

UniProt ID  P33432 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis Binding intracellular targets



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50>250 μg/mL MTT assay 24 h 1

Hemolytic Activity  Sheep erythrocytes: No hemolysis up tp 500 µg/ml

Normal (non-cancerous) Cytotoxicity  NIH 3T3: IC50>250 µg/ml

Target  Not available

Affinity  Not available

Mechanism  Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02831

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C98H123N23O15

Absent amino acids  ACDEHILMNQSY

Common amino acids  W

Mass  207741

Pl  11.82

Basic residues  3

Acidic residues  0

Hydrophobic residues  7

Net charge  3

Boman Index  -898

Hydrophobicity  -96.15

Aliphatic Index  22.31

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  27500

Absorbance 280nm  2291.67

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 33207639

Title  Effects of Rationally Designed Physico-Chemical Variants of the Peptide PuroA on Biocidal Activity towards Bacterial and Mammalian Cells

Doi 10.3390/ijms21228624

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_16982

DRACP is developed by Dr.Zheng's team.